Tuesday turned out to be a nightmare for shareholders of PTC Therapeutics, Inc. (NASDAQ:PTCT) as the stock price tumbled over 55%, after the biotech company received …
Shareholders of biotech firm PTC Therapeutics, Inc. (NASDAQ:PTCT) and financial technology firm On Deck Capital Inc (NYSE:ONDK) are having a rough day, as both companies fell sharply following FDA …
RBC Capital analyst Simos Simeonidis weighed in today on two biotech stocks, Sarepta Therapeutics Inc (NASDAQ:SRPT) and PTC Therapeutics, Inc. (NASDAQ:PTCT), following the release of the FDA Draft Document …
The American Association of Neurology is hosting its annual meeting this week in Washington, DC. Through the end of this week, major biotechnology …
By Donald Moenning Every trading day, we search our database for a stock that, in our humble opinion, is in solid technical condition and …
In a research note published Friday, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on PTC Therapeutics (NASDAQ:PTCT) with a $58 price, …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on PTC Therapeutics (NASDAQ:PTCT) with a price target …
In a research report issued Tuesday, Oppenheimer analyst Christopher Marai maintained an Outperform rating on PTC Therapeutics (NASDAQ:PTCT) with a $60 price target, as …
In a research report released today, analyst Christopher Marai of Oppenheimer maintained an Outperform rating on PTC Therapeutics (NASDAQ:PTCT) with a $60 price target, which represents a potential …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on PTC Therapeutics (NASDAQ:PTCT), and raised his price …
